Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).
Mark Kozloff
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Wells A. Messersmith
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Amy V. Kapp
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Avi Ashkenazi
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Stephanie Royer-Joo
Consultant or Advisory Role - Genentech
Chia C. Portera
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Zev A. Wainberg
Consultant or Advisory Role - Genentech
Honoraria - Genentech